You are here

Home » Content

Akciğer Tüberkülozu Tedavisinin Takibinde Serum Ca-125 ve CEA Düzeyleri

Follow Up of Serum Ca125 and CEA Levels For Treatment of Pulmonary Tuberculosis

Journal Name:

  • Fırat Tıp Dergisi

Publication Year:

  • 2006

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objectives: To determine the levels of Ca125 and CEA those are tumor markers at tuberculosis patients during the treatment. Materials and Methods: In 20 cases that were diagnosed as active pulmonary diagnosis (APT), the serum levels of CA-125 and CEA were measured initially and second and sixth months of the treatment. These results were compared with the results that obtained from 15 inactive pulmonary tuberculosis (IPT) cases and 15 healthy controls. Results: Serum CA-125 levels were higher at APT cases than in IPT cases and controls at the beginning of the treatment (p<0.001, for both). These levels were still higher even if they begin to decrease according to the initial levels at APT cases at 2nd months of the treatment than in IPT and controls were (p<0.01; APT vs. IPT and p<0.005; APT vs. Controls). At 6th months of the treatment, statistically significant differences seen between groups were disappeared (p>0.05). Serum CA-125 levels were decreased as statistically significantly at times of initially, 2nd and 6th months of the treatment (p<0.001). No statistically significant differences were observed from the point view of serum CEA levels in all groups or at duration of treatment. Conclusion: The serum CA-125 levels were high in pulmonary tuberculosis cases and these levels return the normal values with treatment. Thus, we think CA-125 could be used for follow up of tuberculosis treatment. ©2006, Fırat Üniversitesi, Tıp Fakültesi
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Tümör belirleyicileri olan CA-125 ve CEA'nın tüberkülozlu hastalarda tedavi süresince serum düzeylerinin saptanması. Gereç ve Yöntem: Aktif akciğer tüberkülozu tanısı konulan 20 olguda, başlangıç ve tedavinin 2. ve 6. aylarında serum CA-125 ve CEA düzeyleri ölçüldü. Ayrıca elde edilen sonuçlar 15 inaktif tüberküloz olgusu ile 15 sağlıklı kontrol olgusundan elde edilen sonuçlarla karşılaştırıldı. Bulgular: Serum CA-125 düzeyleri aktif grupta tedavi başlangıcında hem inaktif hem de kontrol grubundan anlamlı olarak yüksekti (her iki grup için p<0.001). Tedavinin 2. ayında da bu düzeylerin azalmakla birlikte halen yüksek olduğu gözlendi (aktif-inaktif arası p<0.01 ve aktif kontrol arası p<0.005). Tedavinin 6. ayında tüm gruplar arası istatistiksel anlamlılığın kaybolduğu saptandı (p>0.05). Aktif grupta başlangıç, 2. ve 6. aylarda elde edilen değerler karşılaştırıldığında CA-125 düzeylerinin istatistiksel olarak anlamlı olarak tedavi süresi ilerledikçe azaldığı bulundu (p<0.001). Serum CEA düzeylerinde ise hem gruplar arasında hem de tedavi süresince anlamlı bir farkın olmadığı gözlendi (p>0.05). Sonuç: Sonuç olarak akciğer tüberkülozlu hastalarda serum CA-125 düzeylerinin yüksek olduğunu ve tedavi ile bu düzeylerin azalarak normale döndüğünü bu nedenle CA-125'in hastalığın tedavisini takipte kullanılabilecek bir belirteç olduğunu düşünmekteyiz. ©2006, Fırat Üniversitesi, Tıp Fakültesi
FULL TEXT (PDF): 
PDF icon arastirmax-akciger-tuberkulozu-tedavisinin-takibinde-serum-ca-125-cea-duzeyleri.pdf
  • 2
134-138
  • Turkish

REFERENCES

References: 

1. World Health Organisation. The World Health Report 2000. Health systems: Improving performance. WHO, Geneva, 2000.
2. Hawken M, Nunn P, Gathua S, Brindle R, Godfrey-Faussett P,
Githui W, Odhiambo J, Batchelor B, Gilks C, Morris J, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet. 1993; 342: 332-7.
3. Spence DP, Hotchkiss J, Williams CS, Davies PD. Tuberculosis and poverty. BMJ. 1993 Sep 25; 307: 759-61.
4. American Thoracic Society Documents. Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
5. Saltini C, Colizzi V. Soluble immunological markers of disease activity in tuberculosis. Eur Respir J 1999; 14: 485-6.
6. Simpkins F, Zahurak M, Armstrong D, Grumbine F, Bristow R. Ovarian malignancy in breast cancer patients with an adnexal mass. Obstet Gynecol 2005; 105: 507-13.
7. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984 Dec; 50: 765-9.
8. Berthiot G, Marechal F, Cattan A, Deltour G. Serum levels of CA-50, CA-19.9, CA-125, neuron specific enolase and carcinoembryonic antigen in lung cancer and benign diseases of
the lung. Biomed Pharmacother 1989; 43: 613-20.
9. Buamah P. Benign conditions associated with raised serum CA-
125 concentration. J Surg Oncol 2000; 75: 264-5.
10. Sarobe P, Huarte E, Lasarte JJ, Borras-Cuesta F. Carcinoembryonic antigen as a target to induce anti-tumor immune responses. Curr Cancer Drug Targets 2004; 4: 443-54.
11. Ruibal Morell A. CEA serum levels in non-neoplastic disease. Int
J Biol Markers 1992; 7: 160-6.
12. Yılmaz A, Ece F, Bayramgürler B, Akkaya E, Baran R. The value of Ca 125 in the evaluation of tuberculosis activity. Respir Med
2001; 95: 666-9.
13. Ichiki H, Shishido M, Nishitani K, Takatsugi K, Nishiyama S, Yano M, Watanabe K. Evaluation of CEA, SLX and CA125 in active pulmonary tuberculosis. Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31: 1522-7.
14. Molina R, Filella X, Jo J, Agusti C, Ballesta AM. CA 125 in biological fluids. Int J Biol Markers 1998; 13: 224-30.
15. Diez M, Cerdan FJ, Ortega MD, Torres A, Picardo A, Balibrea JL. Evaluation of serum CA 125 as a tumor marker in non-small cell lung cancer. Cancer 1991; 67: 150-4.
16. Mas MR, Comert B, Saglamkaya U, Yamanel L, Kuzhan O, Ateskan U, Kocabalkan F. CA-125; a new marker for diagnosis and follow-up of patients with tuberculous peritonitis. Dig Liver
Dis 2000; 32: 595-7.
17. Thakur V, Mukherjee U, Kumar K. Elevated serum cancer antigen 125 levels in advanced abdominal tuberculosis. Med
Oncol 2001; 18: 289-91.
18. Uzunkoy A, Harma M, Harma M. Diagnosis of abdominal tuberculosis: experience from 11 cases and review of the
literature. World J Gastroenterol 2004; 10: 3647-9.
19. Mansour M, Linden ER, Colby S, Posner G, Marsh F Jr. Elevation of carcinoembryonic antigen and CA-125 in a patient with multivisceral tuberculosis. J Natl Med Assoc 1997; 89: 142¬3.
20. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vila S, Orriols R. Diagnostic utility of CYFRA 21-1, carcinoembryonic
antigen
, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999; 86: 1488-95.
21. San Jose ME, Alvarez D, Valdes L, Sarandeses A, Valle JM, Penela P. Utility of tumour markers in the diagnosis of neoplastic
pleural effusion. Clin Chim Acta 1997; 265: 193-205.
22. Matsuoka Y, Endo K, Kawamura Y, Yoshida T, Saga T, Watanabe Y, Koizumi M, Nakashima T, Konishi J, Yamaguchi N, et al. Normal bronchial mucus contains high levels of cancer-associated antigens, CA125, CA19-9, and carcinoembryonic antigen. Cancer 1990; 65: 506-10.
23. Hirose T, Ohta S, Sato I, Matsuda M, Arai T, Katsura T, Fukaura
A, Nakajima H, Adachi M. Tuberculous pleuro-peritonitis showing increased levels of CA125. Nihon Kyobu Shikkan Gakkai Zasshi 1997; 35: 196-200.
24. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J,
Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J, Viladiu P. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003;
24: 209-18.
25. Szklarz E, Gawlikowski W. Carcinoembryonic antigen (CEA) in the blood serum of patients with bronchogenic carcinoma and selected diseases of the respiratory tract. Pneumonol Pol. 1989 Apr; 57: 217-21.
26. Safianowska A, Grubek-Jaworska H, Droszcz P, Rybus L, Dabrowski A, Zwolska Z, Matysiak W, Chazan R. Levels of CEA, antibodies against mycobacterial antigens and ACE activity
137
Fırat Tıp Dergisi 2006;11(2): 134-138
in serum and in BALF in patients with sarcoidosis, tuberculosis and lung cancer--preliminary results. Pneumonol Alergol Pol. 2001; 69: 5-13.
27. Garcia-Pachon E, Padilla-Navas I, Dosda MD, Miralles-Llopis A. Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest 1997; 111: 643-7.
28. Riantawan P, Sangsayan P, Bangpattanasiri K, Rojanaraweewong P. Limited additive value of pleural fluid carcinoembryonic
Turgut ve Ark
antigen level in malignant pleural effusion. Respiration 2000; 67:
24-9.
29. Ryu JS, Lee HJ, Cho JH, Han HS, Lee HL. The implication of
elevated carcinoembryonic antigen level in pleural fluid of patients with non-malignant pleural effusion. Respirology 2003;
8: 487-91.

Thank you for copying data from http://www.arastirmax.com